Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 

Smart, Risk-Based Immunogenicity Planning Starts Early

Unexpected immunogenicity can derail even the most promising therapeutics in the clinic. Whether it’s a high titre ADA signal, a neutralizing response, or an unexplained PK shift, surprises in mid- to late-stages of clinical development often trace back to missed opportunities in preclinical development. Fortunately, these surprises are increasingly preventable. 

Drug developers are now expected to consider immunogenicity and accompanying risks not as a single study endpoint, but continuously from discovery to commercialization. Regulators emphasize early, data-driven risk assessment to inform downstream strategy. Incorporating predictive insights early allows developers to identify potential issues, focus resources on critical risks, and design studies that are both efficient and scientifically defensible. 

Predictive immunogenicity tools and fit-for-purpose in vitro assays are transforming how developers approach IND-enabling studies and later stage development phases, resulting in significant return on investment. Instead of reacting to immune responses after they appear, teams can now anticipate them, refine their candidates, and enter the clinic with right-sized and streamlined bioanalytical and clinical immunogenicity strategies. 

This proactive approach aligns with FDA and EMA recommendations to implement risk-based strategies for immunogenicity assessment. Rather than testing indiscriminately, the emphasis is now on making informed, data-driven decisions: testing when risk is meaningful and holding when it’s not. That shift begins with robust risk assessments performed during preclinical stages of development. 

EpiVax scientists have observed this shift towards the use of risk assessment outputs firsthand, and we’re here to help—from start to finish—with in silico, in vitro, consulting, and regulatory support expertise. 

Why Immunogenicity Risk Assessment Data Matters

Early immunogenicity risk assessment is both practical and aligned with regulatory expectations. From a development standpoint, understanding potential immune liabilities before conducting involved IND-enabling regulated studies and clinical testing may avoid development of involved bioanalytical assays or untimely program failures. From a regulatory perspective, agencies increasingly expect sponsors to provide a thorough Immunogenicity Risk Assessment (IRA) as part of their IND submission and an Integrated Summary of Immunogenicity (ISI) as part of their BLA, with an aim to prioritize the identification, mitigation, and monitoring of patient safety risks. 

Multiple data outputs from preclinical risk assessments can be combined to establish the foundation of an IRA: 

• In silico analyses that identify T cell epitopes, evaluate humanness, flag intrinsic sequence risk, and inform the design of confirmatory in vitro assays.
• In vitro assays are considered orthogonal methods of assessment and confirm how immune cells respond when exposed to a candidate molecule in early development as well as in later stages of development. This data supports questions related to the final formulated drug product with any dose, formulation, or device changes. Together, these insights help developers predict the risk of immune response to the therapeutic proteins in patients and build a scientific rationale for the bioanalytical and clinical plans that follow.  

The IRA serves as a summary of assessments of the baseline immunogenicity risk profile, which can be updated throughout clinical stages as more information about observed immune responses and clinical impact is collected, in preparation for the ISI.  

The ISI functions as a living document, bringing together the evolving risk profile, bioanalytical strategy, and clinical data generated throughout development to support a comprehensive immunogenicity assessment and inform risk management and regulatory decision-making. 

Connecting Predictive Tools to a Risk-Based Strategy 

EpiVax’s ISPRI ™ in silico toolkit provides teams with a detailed view of potential immune risk early in development. Using proprietary, validated algorithms, ISPRI evaluates candidate sequences for T cell epitope density and tolerance potential, generating an immunogenicity risk profile well before in vitro or in vivo testing begins. 

EpiVax offers several service options that serve different stages of development. For example, the ISPRI Downselect™ report supports high-throughput screening of many candidates during lead selection, filtering out those with high predicted risk. For more advanced programs, the ISPRI Evaluate™ report provides a comprehensive analysis suitable for IND submission, often paired with in vitro validation. 

These predictive results inform specific next steps: 

• Sequence optimization using protein reengineering tools like OptiMatrix to reduce high-risk T cell epitope regions without altering function. 
• Assay design, ensuring that downstream in vitro and clinical bioanalytical assays are appropriately scaled and fit to assess previously identified risk factors. 
• Clinical monitoring strategy, helping teams anticipate when and where immune responses are most likely to appear.

Predictive modeling complements in vitro assays rather than replacing them. By using in silico insights to design the in vitro experiments, developers can prioritize the most informative assays and reduce redundancy, creating a more time- and cost-efficient plan. 

In Vitro Strategies to Support Risk Assessment Across Development  

In vitro immunogenicity assays are modular and can be deployed at multiple points across the development lifecycle to address distinct risk questions as they arise. Rather than being limited to support early preclinical confirmation of in silico identified immunogenic epitopes, these assays have evolved to evaluate specific aspects of immunogenicity risk based on development stage, modality, and program needs. This flexibility allows teams to apply the right assay at the right time, whether the goal is initial risk characterization, comparison of candidates, or evaluation of emerging risks later in development.  

As programs advance, in vitro strategies support ongoing reassessment of immunogenicity risk in response to real-world changes. Formulation adjustments, process scale-up, manufacturing changes, or new clinical observations may introduce risk factors that were not relevant earlier. Modular assay selection enables targeted investigation of these variables without repeating unnecessary testing. Used in this way, in vitro data complement predictive tools to maintain a current, stage-appropriate risk profile that evolves alongside the program and supports both regulatory expectations and data-driven decision making.  

Translating Preclinical Insights into the IRA Section of Your IND

When preparing an IND, the Immunogenicity Risk Assessment (IRA) section serves to combine predictive and experimental data from preclinical development into a regulatory-ready composition. 

A well-supported IRA includes: 

• A clear summary of identified risk factors and corresponding mitigation strategies, such as sequence deimmunization, formulation refinement, removal of co-eluted host cell proteins, and specification setting for degradation- and post-translational modification-related critical quality attributes. 
• Justification for the proposed bioanalytical assays and clinical monitoring plans.
• A rationale for ongoing risk evaluation throughout later phases.

Regulators expect more than raw data. A strong IRA explains how results shaped downstream choices, not just what testing was performed during clinical stage of development. Pairing in silico and in vitro insights to obtain the relevant outputs shows that immunogenicity risk is being proactively addressed and mitigated rather than reactively managed in later stage trials.  

EpiVax’s tools and assays can help fill IND data gaps. EpiVax experts can compile this information into a comprehensive IRA, which can later be updated into an all-encompassing ISI. 

Integrating Preclinical Insights with Bioanalysis and Clinical Planning 

Immunogenicity assessment doesn’t end at IND submission; the insights gained guide bioanalytical and clinical monitoring strategies. The most successful programs maintain continuous data integration from preclinical to clinical phases and beyond. 

Early risk assessment guides assay readiness, helping determine which methods should be qualified or validated before first-in-human studies. It also informs the timing of sample collection to capture the most likely immune responses and supports event-driven testing, where ADA analysis is performed in response to observed PK or safety changes rather than across all samples. 

EpiVax scientists frequently collaborate with development and bioanalytical teams to ensure these connections are made early. Aligning assay development with predicted risk and interpreting preclinical findings in the clinical context helps ensure every decision is informed by data. 

A Continuous, Informed Approach to Immunogenicity Risk 

Immunogenicity assessment is not just a regulatory checkbox; it’s an adaptive process spanning discovery through commercialization. Each phase informs the next, and successful programs use preclinical insights to guide their entire strategy. 

EpiVax’s predictive tools and in vitro assays make it possible to anticipate and mitigate risk, not just measure it. When integrated into IND creation and bioanalytical design, they provide a data-driven foundation for regulatory confidence and clinical success. 

The EpiVax team’s mission is to help developers apply these insights effectively. With the right preclinical data in hand, teams can move into the clinic not just faster, but smarter. 

Ready to turn preclinical insights into a smarter, risk-based strategy? Connect with our team to see how EpiVax can help you anticipate immune responses and make informed decisions before your candidate reaches the clinic.